Navigation Links
Lawson research team working to personalize cancer care
Date:12/12/2011

LONDON, ON - The Lawson Translational Cancer Research Team (LTCRT) of the Lawson Health Research Institute is one of five groups participating in a new study that seeks to personalize cancer drug treatment.

The Genomics Pathway Sequencing (GPS) study, led by the Princess Margaret Hospital in Toronto, will assess the feasibility of identifying specific genetic markers (mutations) in the DNA of patients' tumours. This information will then be used to identify more targeted treatments.

The Lawson team has developed a process for London where they can obtain a fresh tissue sample from the patient's tumour biopsy. This tissue is sent away to a lab in Toronto where two types of DNA analysis are performed. Within three weeks a report on the cancer's genetic profile is provided to the patient's oncologist. "With this new information, it is hoped the oncologist can deliver a more tailored treatment plan," says Dr. Eric Winquist, lead of the LTCRT and medical oncologist at the London Health Sciences Centre.

Jennifer Malone from London, Ontario was diagnosed with cancer in 2006. Over the next five years, she exhausted all standard cancer treatments. A DNA analysis of her tissue sample identified a mutation in a gene known as KRAS. Fortunately, a study investigating a new drug known to target mutations in KRAS was available at the Princess Margaret Hospital and Jennifer was enrolled.

Since starting the experimental treatment, Jennifer's tumour has regressed and many of her cancer symptoms have improved or disappeared. It is "remarkable and amazing," says Jennifer. "Participating in this study gave me an option where previously no option existed."

While the GPS study is still in early development, the idea of more precisely matching patient treatment to their cancer's individual genetic characteristics holds great promise. "We are excited to be discovering what the future holds for our patients using a personalized approach to cancer treatment," says Dr. Winquist, "and the GPS study is a promising look at what this future may look like."


'/>"/>

Contact: Julia Capaldi
julia.capaldi@lhsc.on.ca
519-685-8500 x75616
Lawson Health Research Institute
Source:Eurekalert

Related biology news :

1. Professor Dr. Alexander (Sandy) Lawson is awarded the 2011 Herman Skolnik Award
2. Lawson researchers take control of cancer
3. Lawson researchers share in $2.2 million grant
4. Lawson research shows Canadians dont believe their eyes
5. Wistar Institute researcher receives New Innovator award from NIH
6. NC State researchers get to root of parasite genome
7. White Mountain Research Station to host climate change conference
8. Stevens awarded $1M for advanced biofuels research
9. Researchers find animal with ability to survive climate change
10. Researchers find an essential gene for forming ears of corn
11. Researchers note differences between people and animals on calorie restriction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/3/2017)... SAN ANTONIO , Feb. 3, 2017  Texas Biomedical ... Dr. Larry Schlesinger as the Institute,s ... of Texas Biomed effective May 31, 2017. He is currently ... and Director of the Center for Microbial Interface Biology at ... Dr. Schlesinger as the new President and CEO of Texas ...
(Date:2/1/2017)... BOSTON, Massachusetts , February 1, 2017 ... and events on emerging technology, announces the availability of a new ... Continue Reading ... ... systems in industrial and collaborative robots. Source: IDTechEx Report "Sensors for ...
(Date:1/25/2017)... 2017 The Elements of Enterprise Information Security ... comprised of a comprehensive set of business processes ... digital identities and providing a secured and documented ... significant number of programs opted by enterprises to ... optimizing processes and changing policies. However, there are ...
Breaking Biology News(10 mins):
(Date:2/23/2017)... RAFAEL, Calif., Feb. 23, 2017 ... U.S. dollars, except per share data, unaudited)Three Months Ended ... ChangeTotal BioMarin Revenue $   ...   22832%$ 1,117$   89026%Aldurazyme Net Product Revenue ... 906538%34823946%Naglazyme Net Product Revenue  ...
(Date:2/23/2017)... , Feb. 23, 2017  MIODx announced today ... two key immunotherapy technologies from the University of ... a method to monitor a patient for response ... and CTLA-4.  The second license extends the technology ... is likely to have an immune-related adverse event ...
(Date:2/23/2017)... ROCHESTER, Minn. , Feb. 23, 2017 /PRNewswire/ ... a new product line of oncolytic vaccinia viruses ... Genelux Corporation as part of Genelux,s proprietary, vaccinia ... "We are excited to enter into a partnership ... time, selected oncolytic vaccinia viruses for use in ...
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... ... during the 12th annual Inventors Recognition Reception at Purdue Research Park ... a faculty member in recognition of outstanding contributions to, and success with, commercializing ...
Breaking Biology Technology: